Background and Objectives Buprenorphine's high‐binding affinity as a partial µ‐opioid
agonist displaces preexisting full agonists causing precipitated withdrawal, which requires …

Background The past two decades have witnessed an epidemic of opioid use disorder
(OUD) in the USA, resulting in catastrophic loss of life secondary to opioid overdoses …

This guideline provides recommendations for clinicians providing pain care, including those
prescribing opioids, for outpatients aged≥ 18 years. It updates the CDC Guideline for …

Background Worsening of the overdose crisis in the USA has been linked to the continuing
proliferation of non-pharmaceutical fentanyl (NPF). The recent wave of NPF spread in the …

Opioid use disorder (OUD) is increasingly recognized as a chronic, relapsing brain disease
whose treatment should be integrated into primary care settings alongside other chronic …

Buprenorphine possesses many unique attributes that make it a practical agent for adults
and adolescents with opioid use disorder (OUD) and/or acute or chronic pain. Sublingual …

Background Induction of buprenorphine, an evidence-based treatment for opioid use
disorder (OUD), has been reported to be difficult for people with heavy use of fentanyl, the …

This paper is the forty-fifth consecutive installment of the annual anthological review of
research concerning the endogenous opioid system, summarizing articles published during …

Although expanding the availability of buprenorphine—a first-line pharmacotherapy for
opioid-use disorder (OUD)—has increased the capacity of healthcare systems to offer …

Abstract Background and Aims Opioid use disorder (OUD) has led to not only increases in
overdose deaths, but also increases in endocarditis and osteomyelitis secondary to injection …